SCHEMBL14716735

SCHEMBL14716735

COc1ccc(N=Nc2nc3nc(NC(C)=O)[nH]c(=O)c3[nH]2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.53
FGFR2 P21802 6/20 0.53
GDA Q9Y2T3 1/20 0.47
FGFR3 P22607 3/20 0.47
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 5/20 0.41
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ESR1 P03372 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14716598 0.84 FGFR1 (0.51) FGFR1FGFR2GDAFGFR3TDP1
SCHEMBL14729742 0.83 TDP1 (0.44) FGFR1FGFR2GDATDP1MAPT
SCHEMBL14716736 0.83 TDP1 (0.44) FGFR1FGFR2GDATDP1MAPT
SCHEMBL14716514 0.79 FGFR1 (0.48) FGFR1FGFR2TDP1MAPTNPC1
SCHEMBL14716705 0.75 FGFR1 (0.53) FGFR1FGFR2GDAFGFR3TDP1
SCHEMBL14716392 0.71 FGFR1 (0.46) FGFR1FGFR2GDAFGFR3TDP1
SCHEMBL12320829 0.70 TDP1 (0.49) FGFR1FGFR2GDAFGFR3TDP1
SCHEMBL16513137 0.70 GDA (0.64) FGFR1FGFR2GDAFGFR3TDP1
SCHEMBL18409069 0.69 NPC1 (0.67) TDP1MAPTNPC1LMNARAB9A
SCHEMBL2435283 0.69 FGFR1 (0.59) FGFR1FGFR2GDAFGFR3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458515-B2 RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound RIKEN (JP) 2016-10-04 US disclosed
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RIKEN (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RNMT, NSUN2, RNGTT FGFR1 4325/4885FGFR2 4803/4885GDA 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.